申请人:PFIZER INC.
公开号:EP0252713A1
公开(公告)日:1988-01-13
A series of novel 3-mono(substituted methyl)- and 3,3-di(substituted methyl)-2-oxo-indoline-1-alkanoic acid compounds have been prepared, including their lower alkyl esters and unsubstituted amide derivatives, as well as the base salts of said acids with pharmacologically acceptable cations. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical members include those compounds derived from 2-oxo-indoline-1-acetic acid wherein a 3,4-dichlorobenzyl or 3,4-dichloro-α-methylbenzyl moiety is substituted at 3-position of the molecule. Preferred member compounds include 3-(3,4-dichlorobenzyl)-2-oxo-indoline-1-acetic acid, 5-chloro-3-(3,4-dichlorobenzyl)-2-oxo-indoline-1-acetic acid, 3-(3,4-dichlorobenzyl)-6-methoxy-2-oxo-indoline-1-acetic acid, 3-(3,4-dichlorobenzyl)-6-hydroxy-2-oxo-indoline-1-acetic acid and 3-(3,4-dichloro-α-methylbenzyl)-2-oxo-indoline-1-acetic acid. Methods for preparing these compounds from known starting materials are provided.
我们制备了一系列新型 3-单(取代甲基)-和 3,3-二(取代甲基)-2-氧代吲哚啉-1-烷酸化合物,包括它们的低级烷基酯和未取代的酰胺衍生物,以及上述酸与药理学上可接受的阳离子的碱式盐。这些化合物可作为醛糖还原酶抑制剂用于治疗,以控制某些慢性糖尿病并发症。典型的成员包括由 2-氧代吲哚啉-1-乙酸衍生的化合物,其中 3,4-二氯苄基或 3,4-二氯-α-甲基苄基在分子的 3 位被取代。优选的成员化合物包括 3-(3,4-二氯苄基)-2-氧代吲哚啉-1-乙酸、5-氯-3-(3,4-二氯苄基)-2-氧代吲哚啉-1-乙酸、3-(3、3-(3,4-二氯苄基)-6-甲氧基-2-氧代-吲哚啉-1-乙酸、3-(3,4-二氯苄基)-6-羟基-2-氧代-吲哚啉-1-乙酸和 3-(3,4-二氯-α-甲基苄基)-2-氧代-吲哚啉-1-乙酸。提供了用已知起始原料制备这些化合物的方法。